Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling

The epidermal growth factor receptor (EGFR) is a key player in the normal tissue physiology and the pathology of cancer. Therapeutic approaches have now been developed to target oncogenic genetic aberrations of EGFR, found in a subset of tumors, and to take advantage of overexpression of EGFR in tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Hintzen, Gabriele, Dulat, Holger J., Rajkovic, Erich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518002/
https://www.ncbi.nlm.nih.gov/pubmed/36185288
http://dx.doi.org/10.3389/fonc.2022.892212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518002/
https://www.ncbi.nlm.nih.gov/pubmed/36185288
http://dx.doi.org/10.3389/fonc.2022.892212

Ejemplares similares